

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

STA Burosumab for treating X-linked hypophosphataemia in adults

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
No specific equality issues other than those related to the disability caused by XLH itself.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
N/a

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
N/a

Approved by Associate Director (name):Richard Diaz

Date: 23/02/2023

Technology appraisals: Scoping

Equality impact assessment for the single technology appraisal of burosumab for treating X-linked hypophosphataemia in adults

Issue date: February 2023